Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial.

Autor: Zhou, Hua-Qiang, Zhang, Ya-Xiong, Chen, Gang, Yu, Qi-Tao, Zhang, Hua, Wu, Guo-Wu, Wu, Di, Lin, Ying-Cheng, Zhu, Jun-Fei, Chen, Jian-Hua, Hu, Xiao-Hua, Lan, Bin, Zhou, Ze-Qiang, Lin, Hai-Feng, Wang, Zi-Bing, Lei, Xiao-Lin, Pan, Suo-Ming, Chen, Li-Ming, Zhang, Jian, Kong, Tian-Dong
Zdroj: Signal Transduction & Targeted Therapy; 8/13/2024, Vol. 9 Issue 1, p1-12, 12p
Databáze: Complementary Index
Externí odkaz: